| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Activator-recruited cofactor 36 kDa component; ARC36; DRIP36; FLJ10956; HSPC126; med4; MED4_HUMAN; Mediator complex subunit 4; Mediator of RNA polymerase II transcription subunit 4; Mediator of RNA polymerase II transcription, subunit 4 homolog; OTTHUMP00000018390; OTTHUMP00000018391; OTTHUMP00000018392; RP11-90M2.2; TRAP/SMCC/PC2 subunit p36 subunit; TRAP36; VDRIP; Vitamin D3 receptor-interacting protein complex 36 kDa component |
| Clonality | |
| Conjugate | |
| Form | Liquid |
| Host | |
| Immunogen | Recombinant Human Mediator of RNA polymerase II transcription subunit 4 protein (167-270AA) |
| Isotype | |
| Product Type | |
| Reactivity | |
| Source | This product is a polyclonal antibody purified from rabbit antiserum. |
| Storage | |
| Target | |
| UniProt # |
Overview
This polyclonal anti-MED4 antibody raised in Rabbit, conjugated with Biotin, tested in ELISA. Designed to detect MED4 in Human for others research.
Key elements and design rationale
- Immunogen: Recombinant Human Mediator of RNA polymerase II transcription subunit 4 protein (167-270AA) — determines epitope; confirm sample prep compatibility.
- Host (Rabbit): Requires anti-rabbit-IgG secondary matching isotype IgG.
- Polyclonal: Multiple epitopes = robust signal; lot-to-lot variability — include controls.
- Isotype (IgG): Match secondary, Protein A/G, and isotype controls to IgG.
- Purification (Protein G purification): Enriches Ig classes; reduces non-specific background.
- Biotin: Streptavidin/avidin amplification; block endogenous biotin in biotin-rich samples.
Biological background
MED4 (also: Activator-recruited cofactor 36 kDa component, ARC36, DRIP36, FLJ10956, HSPC126, med4, MED4_HUMAN, Mediator complex subunit 4, Mediator of RNA polymerase II transcription subunit 4, Mediator of RNA polymerase II transcription, subunit 4 homolog, OTTHUMP00000018390, OTTHUMP00000018391, OTTHUMP00000018392, RP11-90M2.2, TRAP/SMCC/PC2 subunit p36 subunit, TRAP36, VDRIP, Vitamin D3 receptor-interacting protein complex 36 kDa component) — studied in Human systems. Expression, localization, and PTMs vary across cell types and disease states. Consult UniProt, NCBI Gene, and primary literature for current MED4 annotation relevant to others.
Common research applications
- ELISA: Quantify soluble target; ensure samples within the linear detection range.
Notes for experimental interpretation
- Isotype controls: IgG from Rabbit at equivalent concentration.
- Cross-reactivity: Polyclonal: validate with KO/KD controls.
- Matrix effects: Verify dilution linearity in your sample matrix.
- Reactivity: Confirmed for Human; extrapolation requires validation.
This product is a polyclonal antibody purified from rabbit antiserum.
MED4 is a protein studied in Human biology. This polyclonal antibody raised in Rabbit detects MED4 in ELISA applications, IgG isotype.
Reported reactive against Human. Immunogen from Human. Cross-reactivity with untested species requires empirical confirmation.
Reported for ELISA. Optimize dilution/blocking per application. Consult datasheet for working concentrations.
Biotin: streptavidin/avidin amplification. Block endogenous biotin in biotin-rich samples.
(1) Isotype control: IgG from Rabbit; (2) Positive control: lysate/cell line expressing MED4; (3) Negative control: siRNA KD or KO; (4) Dilution linearity in your sample matrix.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
